European SPC Manufacturing Waiver Comes Into Effect
Timeline: Key Events For The Development Of A Waiver To Allow Manufacturing And Stockpiling For Day-One Launch
Executive Summary
In Vivo has traced the history of the newly affirmed European SPC manufacturing waiver from early industry lobbying efforts to its ultimate entry into force. The mechanism has been met with controversy throughout its evolution.
You may also be interested in...
Fixing The UK Market: Government Must Move From ‘Transactional’ To ‘Strategic’ Approach
With the UK market experiencing approval delays, shortages, and regulatory complexity, the government’s “policy vacuum” and complacent approach to off-patent medicines risk undermining the sector, says BGMA chair Diane DiGangi Trench. In an exclusive interview with Generics Bulletin, she urges a shift from a “transactional” to a “strategic” relationship with industry to fully unlock the benefits of generics and biosimilars.
BGMA Warns That Policy Vacuum Risks UK Becoming ‘Supply Backwater’
With a UK general election looming, local generics and biosimilars industry association the BGMA has warned that the country will be “deprioritized as a supply market” without a more focused and supportive policy environment for the off-patent sector.
Meitheal Prepares For Major US Injectables Push
Meitheal Pharmaceuticals says it is preparing to launch “up to 20 new products” this year in the US following a recent expansion of its generic injectables portfolio.